Table 1.

Baseline characteristics of the TAX 324 intent-to-treat population and a subset with biopsies informative for HPV status

Intent-to-treat populationHPV-tested population
TPF (n = 280)PF (n = 259)All (n = 539)HPV− (n = 169)HPV+ (n = 68)All (n = 237)
Sex, n (%)
    Male238 (85.0)213 (82.2)451 (83.7)141 (83.4)54 (79.44)195 (82.3)
    Female42 (15.0)46 (17.8)88 (16.3)28 (16.6)14 (20.6)42 (17.7)
Race, n (%)
    Black26 (9.3)26 (10.0)52 (9.6)27 (16.0)1 (1.5)28 (11.8)
    White236 (84.3)220 (84.9)456 (84.6)130 (76.9)66 (97.1)196 (82.7)
    Other18 (6.4)13 (5.0)31 (5.8)12 (7.1)1 (1.5)13 (5.5)
Age, y
    Median565656575556
    Minimum383333343934
    Maximum828082807180
Anatomic site, n (%)
    Hypopharynx45 (16.1)35 (13.5)80 (14.8)33 (19.5)2 (2.9)35 (14.8)
    Larynx153 (18.9)45 (17.4)98 (18.2)51 (30.2)4 (5.9)55 (23.2)
    Oral cavity36 (12.9)38 (14.7)74 (13.7)25 (14.8)3 (4.4)28 (11.8)
    Oropharynx146 (52.1)140 (54.0)286 (53.1)60 (35.5)59 (86.8)119 (50.2)
Clinical stage, n (%)
    III45 (16.1)51 (19.7)96 (17.8)35 (20.7)14 (20.6)49 (20.7)
    IV195 (69.6)171 (66.0)366 (67.9)106 (62.7)48 (70.6)154 (65.0)
    IVA34 (12.1)27 (10.4)61 (11.3)21 (12.4)6 (8.8)27 (11.4)
    IVB6 (2.1)9 (3.5)15 (2.8)7 (4.1)0 (0)
    Missing1 (0.4)1 (0.2)